April 16, 2013
COLORADO SPRINGS, Colo., April 16, 2013 /PRNewswire/ -- Cannabis Science, Inc. (CBIS) is pleased to announce Sacred Cow Production presents American Drug War II, a film by Kevin Booth, for national release on June 6, 2013, as Dr. Robert Melamede, President and CEO of Cannabis Science, appears in the film and played a production role. The Company also announces that a private screening event of the film will be held on Thursday, April 18, at 8 p.m. at Casselmans in Denver, Colorado.
Despite significant peer-review literature demonstrating the clinical value of cannabinoid-based therapies in the treatment of many life threatening diseases, as well as the promise of medicinalization by the life science industry, U.S. policies regarding industrial cannabinoid research are much more restrictive than the regulatory environment in the European Union.
American Drug War II Director Kevin Booth navigates through the arena of cannabinoid research in the context of current cannabis laws through the experiences of a foster parent to a mortally-ill, pediatric cancer patient. The film includes content focused on the work of Cannabis Science and its President and CEO, Dr. Robert Melamede.
American Drug War II is a sequel to the original American Drug War film, which was released in 2006 and premiered on Showtime in 2008. That film won film festival awards including Best Documentary at the Silver Lake Film Festival, Los Angeles, CA in 2007 and Best Documentary at the DIY Film Festival, Hollywood, CA in 2007. A trailer for the film can be seen at: http://www.youtube.com/user/AmericanDrugWar. Law Enforcement Against Prohibition (LEAP) called American Drug War II 'the most powerful and important documentary to date.'
"We would like to thank Sacred Cow Productions for the opportunity to be a part of this film. American Drug War II provides another challenge to U.S. restrictions of proactive research of cannabinoids as viable treatments supported by recent scientific literature. We believe that this film will play a key role in educating the public, as more American citizens and U.S. states come to understand that medical cannabinoids can effectively treat Karposi's Sarcoma, basal cell skin cancer, and other critical ailments," stated Dr. Robert Melamede, President & CEO, Cannabis Science. In addition to 18 existing states and the District of Columbia that have medical cannabis laws, a similar bill was introduced in March in the New York State Assembly and Senate by a bipartisan group of legislators as the trend toward compassionate acceptance continues.
About Cannabis Science, Inc.
Cannabis Science, Inc. is conducting cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products. Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas. The Company plans to open an office in Amsterdam, Netherlands next month to expand and expedite its global operations.
About CS-TATI-1 and CS-S/BCC-1
Cannabis Science's CS-TATI-1 research program will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1's, PO1's and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
Cannabis Science is currently working to develop preclinical investigations of CS-S/BCC-1 treatment of basal and squamous cell carcinomas. The Company has begun preclinical investigations, which are being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's Sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Vice President of Investor Relations
Dr. Robert Melamede, President